Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Paraproteinemias 2Immunoglobulin Light-chain Amyloidosis 2Breast Neoplasms 2Stomach Neoplasms 1Recurrence 1Postoperative Complications 1Papillomavirus Infections 1Myelodysplastic Syndromes 1Intermittent Fasting 1Colorectal Neoplasms 1Advanced Hormone Receptor-Positive Breast Carcinoma 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Clinical Protocols × 1 year × Clear all
NCT06660368 2026-04-01

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
52 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡